Drug Profile
SB 26
Alternative Names: SB26; TAK-671; ulinastatin-Fc; UTI-FcLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Samsung Bioepis; Takeda
- Class Anti-inflammatories; Cytoprotectives; Furans; Glycoproteins; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins; Uroprotectives
- Mechanism of Action Immunomodulators; Trypsin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pancreatitis
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for phase-I development in Pancreatitis in USA (IV)
- 11 May 2021 Takeda expects approval for acute Pancreatitis in FY 2025 (Takeda pipeline, May 2021)
- 07 May 2020 Samsung Bioepis completes a phase I trial in Healthy volunteers in USA (IV) (NCT03630627)